Panbela Therapeutics Inc. (PBLA)
(Delayed Data from OTC)
$0.40 USD
+0.03 (6.94%)
Updated Jun 4, 2024 03:01 PM ET
4-Sell of 5 4
F Value D Growth D Momentum F VGM
Brokerage Reports
Panbela Therapeutics Inc. [PBLA]
Reports for Purchase
Showing records 61 - 74 ( 74 total )
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Looking into 1Q22, Cash Balance, & Price Target Changes
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology-Looking into 1Q22, Cash Balance, & Price Target Changes
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Longer Duration of Survival Observed in Phase I Pancreatic Cancer Trial
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- Catalysts from Our Coverage Universe: YE2021 and Beyond
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
3Q21: Initiation of Two Clinical Trials by YE2021
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
"Consider Reading" Vol 21: Polyamine Inhibition Promotes T-cell Viability in Animals & Implications for PBLA
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
We are initiating with a Buy rating and $10 PT.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T